

# Georg StÃ¼ssli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3193456/publications.pdf>

Version: 2024-02-01

82  
papers

2,281  
citations

279798

23  
h-index

223800

46  
g-index

83  
all docs

83  
docs citations

83  
times ranked

4111  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. <i>Lancet, The</i> , 2014, 383, 436-448.	13.7	322
2	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015, 21, 1628-1638.	7.0	237
3	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.	1.4	223
4	ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 1006-1013.	2.0	124
5	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	7.0	92
6	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	1.4	86
7	Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. <i>Haematologica</i> , 2012, 97, 116-122.	3.5	81
8	HLA-G Inhibits Rolling Adhesion of Activated Human NK Cells on Porcine Endothelial Cells. <i>Journal of Immunology</i> , 2001, 167, 6002-6008.	0.8	74
9	Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. <i>Haematologica</i> , 2009, 94, 239-248.	3.5	73
10	Reactivity of Human Natural Antibodies to Endothelial Cells From Gal $\alpha$ (1,3)Gal-Deficient Pigs. <i>Transplantation</i> , 2007, 83, 193-201.	1.0	68
11	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 465-473.	2.5	46
12	Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 608-616.	2.0	43
13	Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. <i>British Journal of Haematology</i> , 2001, 113, 251-253.	2.5	42
14	Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2122-2129.	0.7	41
15	ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. <i>Transfusion and Apheresis Science</i> , 2006, 35, 59-69.	1.0	34
16	Brief Exercise Increases Peripheral Blood NK Cell Counts without Immediate Functional Changes, but Impairs their Responses to ex vivo Stimulation. <i>Frontiers in Immunology</i> , 2013, 4, 125.	4.8	32
17	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , 2018, 103, e245-e248.	3.5	29
18	The sympathomimetic agonist mirabegron did not lower <i>JAK2</i> V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. <i>Haematologica</i> , 2019, 104, 710-716.	3.5	29

#	ARTICLE	IF	CITATIONS
19	Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. <i>Hematological Oncology</i> , 2019, 37, 595-600.	1.7	28
20	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , 2019, 104, 1633-1639.	3.5	28
21	Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. <i>European Journal of Haematology</i> , 2009, 82, 194-200.	2.2	27
22	Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. <i>Cancer Epidemiology</i> , 2017, 46, 85-92.	1.9	27
23	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. <i>Haematologica</i> , 2020, 105, 2584-2591.	3.5	27
24	Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. <i>Journal of Immunological Methods</i> , 2019, 475, 112348.	1.4	26
25	Red Blood Cells: Exchange, Transfuse, or Deplete. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 407-416.	1.6	25
26	Flow Cytometric Measurement of ABO Antibodies in ABO-Incompatible Living Donor Kidney Transplantation. <i>Transplantation</i> , 2007, 84, S20-S23.	1.0	24
27	Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). <i>Leukemia and Lymphoma</i> , 2014, 55, 87-91.	1.3	23
28	Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1548-1560.	1.3	23
29	ABO-incompatible kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, Publish Ahead of Print, 376-85.	1.6	20
30	Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1029-1037.	2.4	18
31	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1751-1759.	7.2	18
32	Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 173-174.	3.0	17
33	Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. <i>Blood Advances</i> , 2020, 4, 3699-3707.	5.2	17
34	Acral Necrosis of the Fingers as Initial Manifestation of Cutaneous Polyarteritis Nodosa. <i>Angiology</i> , 2001, 52, 63-67.	1.8	16
35	Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. <i>Annals of Hematology</i> , 2011, 90, 89-94.	1.8	15
36	Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 833-836.	2.1	15

#	ARTICLE	IF	CITATIONS
37	Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2011, 96, 119-127.	3.5	14
38	Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. <i>Cancer Epidemiology</i> , 2019, 59, 51-57.	1.9	14
39	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <i>Blood Advances</i> , 2020, 4, 4267-4277.	5.2	14
40	Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.. <i>Xenotransplantation</i> , 2006, 13, 126-132.	2.8	13
41	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.	5.2	12
42	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. <i>Blood Advances</i> , 2021, 5, 4674-4685.	5.2	10
43	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. <i>Cancer Epidemiology</i> , 2018, 52, 55-62.	1.9	8
44	Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. <i>Swiss Medical Weekly</i> , 2011, 141, w13203.	1.6	8
45	The changing paradigm of chronic lymphocytic leukemia management. <i>European Journal of Internal Medicine</i> , 2013, 24, 401-410.	2.2	7
46	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.	1.4	7
47	Unusual Case of Progressive Multifocal Leukoencephalopathy After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, e33-e34.	1.6	6
48	Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. <i>Blood</i> , 2016, 128, 4187-4187.	1.4	6
49	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.	1.8	5
50	ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. <i>Swiss Medical Weekly</i> , 2007, 137, 13-20.	1.6	5
51	Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 664-665.	2.5	4
52	Bone Marrow Involvement in Unknown Acute Myeloid Leukemia Detected by 18F-FDG PET/MRI. <i>Clinical Nuclear Medicine</i> , 2015, 40, e486-e487.	1.3	4
53	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2021, 13, 3296.	3.7	4
54	Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. <i>Blood</i> , 2016, 128, 3108-3108.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. <i>Swiss Medical Weekly</i> , 2013, 143, w13757.	1.6	4
56	A qualitative exploration of interactional and organizational determinants of collaboration in cancer palliative care settings: Family membersâ€™, health care professionalsâ€™ and key informantsâ€™ perspectives. <i>PLoS ONE</i> , 2021, 16, e0256965.	2.5	4
57	Extranodal <sc>NK</sc>/<sc>T</sc>-cell lymphoma with leukaemic presentation. <i>British Journal of Haematology</i> , 2013, 161, 754-754.	2.5	3
58	Castleman's disease and arterial thrombosis: result of excessively elevated interleukin-6 plasma level?. <i>Vasa - European Journal of Vascular Medicine</i> , 2012, 41, 145-148.	1.4	3
59	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019, 134, 2569-2569.	1.4	3
60	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9562.	2.6	3
61	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.	1.4	3
62	Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS. <i>Hematological Oncology</i> , 2020, 38, 197-200.	1.7	2
63	Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. <i>Blood</i> , 2012, 120, 3906-3906.	1.4	2
64	Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997â€“2016. <i>Swiss Medical Weekly</i> , 2018, 148, w14589.	1.6	2
65	Hypereosinophilia with a low blast count as the initial manifestation of acute myeloid leukaemia with <i>RUNX1â€“RUNX1T1</i>. <i>British Journal of Haematology</i> , 2009, 146, 346-346.	2.5	1
66	Erythroblastic islands. <i>British Journal of Haematology</i> , 2010, 150, 499-499.	2.5	1
67	International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278.	0.4	1
68	The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. <i>Blood</i> , 2015, 126, 4005-4005.	1.4	1
69	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. <i>Blood</i> , 2014, 124, 1782-1782.	1.4	1
70	Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2551-2551.	1.4	1
71	Erythroleukaemia at second glance. <i>European Journal of Haematology</i> , 2011, 86, 358-359.	2.2	0
72	Optimised radiological diagnosis of hepatic fungal infection during the treatment of leukemia. <i>Mycoses</i> , 2012, 55, 447-453.	4.0	0

#	ARTICLE	IF	CITATIONS
73	Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantation. Bone Marrow Transplantation, 2021, 56, 2024-2026.	2.4	0
74	Continuous Complete Molecular Remission after Withdrawal of Imatinib Mesylate in Relapsed CML after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 4686-4686.	1.4	0
75	High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.. Blood, 2006, 108, 5352-5352.	1.4	0
76	5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07). Blood, 2010, 116, 2181-2181.	1.4	0
77	Transfusion of Cryopreserved Autologous Platelets to Overcome HLA Alloimmunization in Patients with Hematological Malignancies,. Blood, 2011, 118, 3375-3375.	1.4	0
78	Allogeneic Transplantation for Multiple Myeloma – the Swiss Experience. Blood, 2011, 118, 3112-3112.	1.4	0
79	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4367-4367.	1.4	0
80	Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012. Blood, 2016, 128, 5539-5539.	1.4	0
81	Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research). Blood, 2018, 132, 2875-2875.	1.4	0
82	I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. Blood, 2019, 134, 4752-4752.	1.4	0